PRODUCT OVERVIEW
NanoSphere’s initial product deployment is for the cannabinoid market, targeting both the medical marijuana market and, where legalized, the recreational usage market. NanoSphere has already partnered with a licensee in Colorado, and has launched its first award-winning cannabinoid product line, branded Evolve NanoSerum™, in the Colorado market. NanoSphere will further license its intellectual property and proprietary manufacturing method to selected cannabis cultivators, extractors and distributors on a state-by-state basis and abroad, and is currently in discussions with operators in several states to replicate the business model in Colorado. Other planned future deployments include nutraceuticals, non steroidal anti-inflammatory drugs and animal health applications.
66
PIONEERING NANO-BIOTECHNOLOGY COMPANY. WITH OVER 20 YEARS RESEARCHING AND DEVELOPING OUR PATENT-PENDING NANOSPHERE DELIVERY SYSTEM™.
PATENTED NANOSPHERE DELIVERY TECHNOLOGY™ INCREASES THE BIOAVAILABILITY AND BIOACTIVITY OF CANNABINOIDS.
NANOSPHERE HEALTH IS THE FIRST AND ONLY COMPANY TO NANO-SIZE AND ENCAPSULATE CANNABINOIDS, DRAMATICALLY CHANGING THE INDUSTRY.
Q& A
PRODUCT OVERVIEW
NanoSphere’s initial product deployment is for the cannabinoid market, targeting both the medical marijuana market and, where legalized, the recreational usage market. NanoSphere has already partnered with a licensee in Colorado, and has launched its first award-winning cannabinoid product line, branded Evolve NanoSerum™, in the Colorado market. NanoSphere will further license its intellectual property and proprietary manufacturing method to selected cannabis cultivators, extractors and distributors on a state-by-state basis and abroad, and is currently in discussions with operators in several states to replicate the business model in Colorado. Other planned future deployments include nutraceuticals, non steroidal anti-inflammatory drugs and animal health applications.
CI: What are your growth projections?
NSHSF: Simply put, we’re not just a cannabis company. Our technology is
useful in the supplements and vitamin industry because it bypasses putting those through your digestive system; instead of getting 10 or 15% bioactivity, you’re getting 80%. We also have patents that are pending on NSAIDs, which will be revolutionary in the delivery of anti-inflammatories. The key is that if you don’t go through the digestive system, you don’t have the stomach issues, you don’t have liver issues, et cetera. In addition, we have products that we have planned for the animal health industry.
Over the next couple of years, we want to be in at least 50% of the markets in the United States as well as being completely operational in Canada and potentially another international locations. We’re always going to increase our product lines, creating different formulas to elicit different effects. But where I really see this going, is once the cannabis division has really established itself, we’re going to begin focusing on our other divisions. Our patent on the NSAIDs technology is an enormous opportunity, almost beyond what cannabis is, for pharmaceutical applications and increased bioavailability of them. I see us conducting more R&D on the NSAIDs, hopefully entering into a license agreement with a big pharma company, or even spinning that division completely off. From there, we’ve got our nutraceuticals we’ll begin to do again as well as animal health products.
The opportunities for increased delivery and increased efficacy are almost boundless. This is an exciting time to be a part of NanoSphere, whether as a licensee, an investor, or a consumer. We’re going on a journey here and I think anyone that comes with us for the ride is going to be happy they did.
CI: How much convertible or dilutive debt do you have?
NSHSF: None.
CI: Will you need to raise capital in the short-term and long-term? Approximately how much capital will you need to raise?